[Tumor response in comparative trials].
Survival improvement is the main aim of most cancer trials. Tumor response is a very common end-point in this context, as it permits a quick answer. It is useful criterion for screening in phase II trials, but cannot be utilised in phase III comparative trials for several reasons put forward in this article.
Laplanche
A
A
Département de biostatistique et d'épidémiologie, institut Gustave-Roussy, Villejuif, France.
D003627:Data Interpretation, Statistical; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000401:mortality; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis
La résponse tumorale dans les essais comparatifs.